A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …

Standard induction chemotherapy, consisting of an anthracycline and cytarabine, has been
the first-line therapy for many years to treat acute myeloid leukemia (AML). Although this …

Acute myeloid leukemia (AML) is a polyclonal and heterogeneous hematological
malignancy. Relapse and refractory after induction chemotherapy are still challenges for …

Acute myeloid leukemia (AML) is a hematological malignancy characterized by cytogenetic
and genomic alterations. Up to now, combination chemotherapy remains the standard …

Relapse is common in acute myeloid leukemia (AML) and thought to be due to resistance of
underlying leukemic stem cells (LSCs) to current standard therapies, although a lack of tools …

Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults. While
complete remission can be obtained with intensive chemotherapy in young and fit patients …

Most adult patients with acute myeloid leukemia (AML) die from their disease. Relapses are
frequent even after aggressive multiagent chemotherapy and allogeneic stem cell …

Despite an increasingly rich understanding of its pathogenesis, acute myeloid leukemia
remains a disease with poor outcomes, overwhelmingly due to disease relapse. In recent …

Simple Summary Relapse after apparent remission remains a major cause of death in
patients with acute myeloid leukemia (AML). On the cellular level, leukemia relapse is …

Hematopoietic stem cells (HSC) are responsible for the production of mature blood cells. To
ensure that the HSC pool does not get exhausted over the lifetime of an individual, most …